Vinorelbine liposomal - Taiwan Liposome Company

Drug Profile

Vinorelbine liposomal - Taiwan Liposome Company

Alternative Names: Nanoliposomal vinorelbine - Taiwan Liposomal Company; TLC-178; Vinorelbine encapsulated liposome - TLC

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiwan Liposome Company
  • Class Antineoplastics; Small molecules; Vinca alkaloids
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Lymphoma; Solid tumours
  • Preclinical Rhabdomyosarcoma
  • No development reported Non-Hodgkin's lymphoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in Taiwan (Parenteral, Liposomal)
  • 11 Jul 2017 Taiwan Liposome Company has patent protection for vinorelbine liposomal in USA
  • 27 Apr 2017 Phase-I/II clinical trials in Lymphoma (Late-stage disease) in Taiwan, USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top